MBAPL's Q1 inventory tailwind is gone. Guidance stays vague.
Q1 EBITDA rose 16% on low-cost raw material stock, now exhausted. Management promises >50% turnover jump but won't give full-year numbers. Expansion on track. Equity dilution on the table.
— 1 earlier story on Madhya Bharat Agro Products Ltd. →What's new
- Q1 EBITDA rose 16% to ₹66 cr on low-cost inventory; benefit now exhausted.
- Management guided for >50% turnover growth but declined to restate FY27 quantitative targets.
- Dhule Phase 2 on track for Oct 2026; future expansion may involve equity dilution.
Why this matters
The EBITDA beat was real but non-recurring. With inventory tailwinds gone, margin sustainability is the open question. Management hinted at equity dilution for future expansion, a shift from prior debt-funded stance. At 33x P/E, the stock priced in compounding without dilution. That assumption is now weaker.
What we're watching
- Capacity utilization ramp-up to 90% in coming quarters.
- Any update on capex overrun and funding mix for Dhule Phase 2.
- Management's next mention of equity dilution. If concrete, multiple re-rating risk.
The full read
Madhya Bharat Agro's Q1 was saved by low-cost inventory. Revenue of ₹416 crore grew just 1.6% YoY. EBITDA jumped 16% to ₹66 crore. That cushion is gone. The Dhule Phase 2 expansion is on schedule for October 2026, adding 3.3 lakh tonnes of capacity. But current utilization sits at 79% for SSP and 66% for NPK-DAP, constrained by raw material shortages and late monsoons. Management talks up a >50% turnover increase in coming months but won't restate a full-year number. A bigger shift: future expansion may tap equity. At 33x trailing earnings, the stock priced in growth without dilution. That assumption is now weaker. The next test is whether capacity utilization climbs and whether management's guidance holds without the inventory crutch — the margin story has shifted from tailwind to headwind.
Questions answered
- Why did EBITDA grow faster than revenue in Q1?
- EBITDA was boosted by low-cost raw material inventory purchased earlier. That benefit is now fully exhausted, so margins may normalize in coming quarters.
- What is the exact low-cost inventory benefit?
- Management did not quantify the exact benefit, but attributed the 16% EBITDA growth to favourable raw material costs. They explicitly stated this benefit has been used up.
- Why is capacity utilization low despite expansion?
- Q1 utilization was 79% for SSP and 66% for NPK-DAP due to raw material shortages and delayed monsoons. Management expects a ramp-up to 90% as supply normalises.
- When will the Dhule Phase 2 come online?
- The integrated fertilizer complex Phase 2 is on track for commissioning in October 2026, adding 3.3 lakh metric tonnes of DAP-NPK capacity.
- Is equity dilution certain for future expansion?
- Management indicated that while current expansions are funded through debt and internal accruals, future large-scale phases could involve equity dilution. No specifics were provided.
- Is the >50% turnover growth guidance credible?
- Management declined to provide quantitative full-year targets, making the guidance non-binding. Credibility depends on capacity utilization ramp-up and raw material availability in coming months.
Madhya Bharat Agro Products Ltd.
Latest quarter · Mar 2022
Strength & growth
Story so far
All notes on MBAPL →- 15 Jul 2026 · 5:07 PM IST MBAPL's Q1 inventory tailwind is gone. Guidance stays vague.
- 43d ago Madhya Bharat Agro targets 60-70% FY27 growth on new plants; capex overruns 40%